Excellence in Dermatology™
Excellence in Dermatologic Surgery™
Excellence in Medical Dermatology™
Excellence in Dermatopathology™

U037 - Bureaucracy, Compliance, and Burnout: What it Means to Dermatologists

Saturday, February 17; 4:30 PM - 5:30 PM

Learning Objectives

Following this course, the attendee should be able to:

  • Examine the social, economic, and bureaucratic forces shaping the practice of dermatology in America
  • Identify the factors contributing to anxiety, frustration, and despondency for dermatologists
  • Formulate lifelong strategies to identify, prevent, and combat burnout in our specialty

Description

This panel discussion/Q&A will analyze the factors (regulatory, social, & economic) contributing to frustration, anxiety, and despondency for dermatologists, whether employed or in private practice. We will explore what the future holds in our increasingly complex environment and discuss strategies to mitigate burnout for dermatologists.

Disclosures

  • Bhatia, Neal D., MD: AbbVie – I(Grants/Research Funding); Aclaris Therapeutics, Inc. – I(Grants/Research Funding); Actavis – I(Grants/Research Funding); Allergan, Inc – C(H); Almirall – C(H); Asana Biosciences, LLC – I(Grants/Research Funding); Atacama Therapeutics – I(Grants/Research Funding); Biofrontera AG – C(H); BioPharmX – I(Grants/Research Funding); Brickell Biotech, Inc. – I(Grants/Research Funding); Crown Laboratories, Inc. – I(Grants/Research Funding); Cutanea Life Sciences – I(Grants/Research Funding); Dermira – I(Grants/Research Funding); DUSA Pharmaceuticals, Inc. – I(Grants/Research Funding); Ferndale Laboratories, Inc. – C(H); Foamix – I(Grants/Research Funding); Galderma Laboratories, L.P. – C(H); Glenmark Generics Inc. – I(Grants/Research Funding); IntraDerm Pharmaceuticals – C(H); ISDIN – C(H); La Roche-Posay Laboratorie Pharmaceutique – C(H); LEO Pharma, US – I(Grants/Research Funding); Mayne Pharma Group – C(H); MC2 Therapeutics – I(Grants/Research Funding); Menlo Therapeutics – I(Grants/Research Funding); Novartis Pharmaceuticals Corp. – C(H); Ortho Dermatologics – C(H); Par Pharmaceutical – I(Grants/Research Funding); Perrigo Company – I(Grants/Research Funding); Pfizer Inc. – I(Grants/Research Funding); Pierre Fabre Dermo-Cosmétique US – C(H); Promius Pharma, LLC – A(H); Realm Therapeutics – I(Grants/Research Funding); Sanofi/Regeneron – C(H), I(Grants/Research Funding); Sienna Biopharmaceuticals – I(Grants/Research Funding); Skinfix, Inc. – A(H); Sol-Gel Technologies – I(Grants/Research Funding); Soligenix, Inc – I(Grants/Research Funding); Strata Skin Sciences – I(Grants/Research Funding); Sun Pharmaceutical Industries Ltd. – C(H); UCB – I(Grants/Research Funding); Valeant Pharmaceuticals International – C(H); Vidac Pharma – I(Grants/Research Funding);
  • Kaufmann, Mark D., MD: Almirall – C(Fees); Cutanea Life Sciences – C(Fees); Dermira – C(Fees); Galderma Laboratories, L.P. – C(Fees); IntraDerm Pharmaceuticals – C(Fees); ISDIN – C(Fees); Klara/Goderma, Inc. – C(SO); L'Oreal USA Inc. – C(Fees); La Roche-Posay Laboratorie Pharmaceutique – C(Fees); Menlo Therapeutics – C(Fees); Modernizing Medicine – C(SO); Ortho Dermatologics – C(Fees); Pfizer Inc. – C(Fees); Promius Pharma, LLC – C(Fees); SciBASE – C(Fees); Sensus Healthcare – C(Fees); UCB – C(Fees);
  • Knight, J. Matthew, MD: no financial relationships exist with commercial interests.
  • Olbricht, Suzanne, MD: no financial relationships exist with commercial interests.
Schedule
Saturday, February 17
4:30 PM
Dr. Knight / Intro
4:35 PM
Dr. Kaufmann / Bureaucracy & Compliance
4:50 PM
Dr. Bhatia / Social Media & Commoditization
5:00 PM
Dr. Olbricht / What do we do now?
5:10 PM
Dr. Knight / Concluding Remarks
5:15 PM
All faculty / Q&A
Event Details
  • Date
    Saturday, February 17
  • Time
    4:30 PM - 5:30 PM
  • Location
    Room 3
  • CME Credits
    1.00
  • Type
    Practice Management
Directors/Co-Directors
  • J. Matthew Knight, MD, FAAD
Speakers
  • Mark D. Kaufmann, MD, FAAD - Handout
  • Neal D. Bhatia, MD, FAAD - Handout
  • Suzanne Olbricht, MD, FAAD